CA209-759: Blood-borne biomarkers for tumor response to Nivolumab in KRAS-mutated non-small cell lung cancer
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics
- 06 Jun 2017 Status changed from not yet recruiting to recruiting, according to results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2017 Results (n=6) assessing plasma circulating tumor DNA as early biomarker (1 week) for tumor response to PD-1 therapy, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 09 Feb 2017 New trial record